Status:
RECRUITING
Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression
Lead Sponsor:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Collaborating Sponsors:
Azienda Ospedaliera Universitaria Integrata Verona
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Conditions:
IPMN, Pancreatic
Eligibility:
All Genders
18+ years
Brief Summary
Intraductal papillary mucinous neoplasms (IPMN) are one of the main precursor lesions of pancreatic ductal adenocarcinoma (PDAC), a lethal disease predicted to become the second leading cause of cance...
Detailed Description
\*\*AIM1.\*\* 1. \*\*Identification\*\* of genes and biological pathways associated with IPMN malignant transformation. The investigators aim to explore the molecular dynamics of tumor progression, f...
Eligibility Criteria
Inclusion
- Diagnosis of indolent IPMN under monitoring;
- Diagnosis of malignant IPMN or resectable pancreatic adenocarcinoma with associated IPMN (previously untreated); Written informed consent; Male and female patients aged 18 years or older;
Exclusion
- Inability to provide written informed consent or to trace patients for the retrospective study.
Key Trial Info
Start Date :
May 29 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
3600 Patients enrolled
Trial Details
Trial ID
NCT06574373
Start Date
May 29 2025
End Date
December 31 2026
Last Update
September 3 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Gemelli
Roma, Italy, 00168
2
IRCCS Fondazione Policlinico Universitario A. Gemelli
Rome, Italy, 00168